aRussian-American Anti-Cancer Center, Altai State University, Barnaul, 656049 Russia
bThe Biodesign Institute, Center for Innovation in Medicine, Arizona State University, Tempe, AZ 85281, USA
cDepartment of Microbiology and Immunology, Center for Vascular and Inflammatory Diseases, Program in Oncology, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, 21201, USA
dFSRI SRC VB Vector, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk oblast, 630559 Russia
1Abbreviations: CAR, Chimeric Antigen Receptor; EAE, Experimental Autoimmune Encephalomyelitis; МНС, Major Histocompatibility Complex; TCR, T Cell Receptor; TNFα, Tumor Necrosis Factor α; Tregs, regulatory T-cells; Th1/Th2, T helper cells of type 1 or type 2; VEGF, Vascular Endothelial Growth Factor; АDCC, Antibody-Dependent Cellular Cytotoxicity; APC, antigen-presenting cell; DC, dendritic cell; CIA, Collagen-Induced Arthritis; LPS, Lipopolysaccharide; mAb, monoclonal antibody; ICM, immune checkpoint molecule; NK, normal killer; CTL, cytotoxic Т-lymphocyte.Received 24 August, 2018
Keywords: the B7 family, immune checkpoint molecules, immunotherapy, T-lymphocytes, the APC ligands
DOI: 10.1134/S1068162019050091